Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Kosin Med J > Epub ahead of print > Article
Case report
Clinically probable ceftriaxone-associated immune thrombocytopenia after foot surgery under peripheral nerve blocks in a hemodialysis patient: a case report
Hyung Gyu Parkorcid, Won Jangorcid, Yong Hyun Choorcid
> Epub ahead of print
DOI: https://doi.org/10.7180/kmj.26.171
Published online: August 31, 2026

Department of Anesthesiology and Pain Medicine, Seoul Sungsim General Hospital, Seoul, Korea

Corresponding Author: Hyung Gyu Park, MD Department of Anesthesiology and Pain Medicine, Seoul Sungsim General Hospital, 259 Wangsan-ro, Dongdaemun-gu, Seoul 02488, Korea. Tel: +82-2-966-1616 Fax: +82-2-968-2394 E-mail: 1003ok@naver.com
• Received: April 15, 2026   • Revised: June 4, 2026   • Accepted: June 16, 2026

© 2026 Kosin University College of Medicine.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 714 Views
  • 6 Download
  • Drug-induced immune thrombocytopenia (DITP) is a rare but potentially life-threatening adverse drug reaction characterized by a rapid decrease in platelet count. Ceftriaxone, a third-generation cephalosporin widely used to treat postoperative infections, has rarely been associated with DITP. This report describes a severe case of clinically probable ceftriaxone-associated DITP in a 68-year-old female patient with end-stage renal disease on maintenance hemodialysis who underwent foot fracture surgery under peripheral nerve blocks. The patient developed severe thrombocytopenia (3,000/µL) four days after ceftriaxone was initiated for postoperative fever. Other potential causes, including disseminated intravascular coagulation, heparin-induced thrombocytopenia, thrombotic microangiopathy, and sepsis, were considered but were not supported by the available data. The Naranjo Adverse Drug Reaction Probability Scale score was 7, and the George criteria were also consistent with a probable causal relationship; rechallenge was not performed because of safety concerns. After ceftriaxone was discontinued, the patient’s platelet count gradually recovered. Because ceftriaxone-dependent platelet antibody testing was unavailable, this case was classified as clinically probable rather than serologically confirmed. This case underscores the diagnostic difficulty of DITP in the perioperative setting and the need for anesthesiologists to consider immune-mediated mechanisms when acute postoperative thrombocytopenia occurs, particularly in patients with altered drug clearance, such as those with end-stage renal disease.
Drug-induced immune thrombocytopenia (DITP) is an immunologic disorder in which drug-dependent antibodies bind to glycoproteins on the platelet surface, accelerating platelet destruction [1,2]. DITP typically occurs within days of exposure, with a rapid, severe platelet decline to less than 20,000/µL [3]. Diagnosis rests on excluding other causes and observing platelet recovery after discontinuation, which is challenging in postoperative patients receiving multiple medications [4]. Ceftriaxone, a widely used third-generation cephalosporin, is rarely associated with DITP [5,6].
We present a case of clinically probable ceftriaxone-associated DITP in a patient with end-stage renal disease (ESRD) on maintenance hemodialysis, who received the antibiotic for a postoperative infection after foot fracture surgery, illustrating the diagnostic challenges in this setting and the value of structured causality assessment when confirmatory antibody testing is unavailable.
Ethical statements: This case report was confirmed to be exempt from review by the Public Institutional Bioethics Committee designated by the Ministry of Health and Welfare, Republic of Korea (exemption No. P01-202603-01-048). The requirement for informed consent was waived.
A 68-year-old female patient was admitted for open reduction and internal fixation of multiple foot fractures caused by a fall. The patient had been on maintenance hemodialysis for ESRD for 20 years, with a medical history of hypertension, type 2 diabetes mellitus, a previous left middle cerebral artery territory infarction, and angina pectoris. The patient underwent heparin-free hemodialysis on the morning before the surgery. Aspirin and clopidogrel were discontinued five days prior to the surgery, and her platelet count on the morning of the procedure was 151,000/µL. Her baseline platelet count over the preceding year had remained stable (130,000–160,000/µL).
Considering her general condition and underlying comorbidities, the surgery was performed under ultrasound-guided femoral and popliteal sciatic nerve blocks instead of general anesthesia. The anesthesia and surgical procedures proceeded without complications. No nonsteroidal anti-inflammatory drugs were administered for postoperative analgesia, given the patient’s ESRD. Prophylactic cefazolin (1 g/day) was administered, and on dialysis days, it was given after the dialysis session.
On postoperative day (POD) 2, following routine hemodialysis, the patient developed a fever of 37.9°C and showed an elevated C-reactive protein level of 14.8 mg/dL. Because a worsening infection was suspected, the antibiotic regimen was switched to intravenous ceftriaxone (2 g/day) starting on POD 3, at which time her platelet count was 126,000/µL.
On POD 7, 4 days after ceftriaxone initiation, a predialysis blood test revealed a precipitous platelet drop to 9,000/µL. Vital signs were stable, with no purpura, petechiae, or other signs of active bleeding. A follow-up test after the heparin-anticoagulated hemodialysis session showed a further decline in the platelet count to 3,000/µL, after which ceftriaxone was discontinued and the patient was transferred to a tertiary hospital for hematology evaluation. At the tertiary hospital, repeat testing confirmed critical thrombocytopenia (<5,000/µL). On further evaluation, the prothrombin time (PT) and international normalized ratio (INR) were normal, the activated partial thromboplastin time (aPTT) was mildly prolonged and the D-dimer mildly elevated, the lactate dehydrogenase (LDH) and bilirubin were normal, and the peripheral blood smear showed no schistocytes; the mean platelet volume (MPV) was elevated at 18.1 fL (reference range, 7.2–11.1 fL). These findings were used to exclude disseminated intravascular coagulation (DIC) and to evaluate heparin-induced thrombocytopenia (HIT), thrombotic microangiopathy, and sepsis as alternative causes. Ceftriaxone-associated DITP was suspected from the temporal relationship with drug administration.
On POD 8, the platelet count spontaneously increased to 32,000/µL without any specific intervention, and the MPV decreased to 11.3 fL. The patient was transferred back to our institution after the hematologist considered ceftriaxone-associated DITP the most likely diagnosis; a repeat count at our institution later that day was 11,000/µL, a discrepancy most likely reflecting inter-laboratory variability or transient fluctuation during early recovery. The antibiotic regimen was changed to ciprofloxacin (400 mg/day), a quinolone with a lower risk of inducing thrombocytopenia.
On POD 9, despite a slight platelet recovery to 38,000/µL after heparin-free hemodialysis, the patient experienced transient hematochezia with a hemoglobin drop from 10.8 to 8.2 g/dL, indicating gastrointestinal bleeding. Vital signs remained stable, and the event was managed conservatively with fasting and an intravenous proton pump inhibitor.
On POD 10, although the platelet count spontaneously recovered to 66,000/µL, an ongoing decline in hemoglobin to 7.9 g/dL—indicative of persistent bleeding—prompted the transfusion of eight units of platelet concentrates to secure hemostasis. Following heparin-free hemodialysis on POD 11, the platelet count increased markedly to 224,000/µL. By POD 14, with a stable platelet count of 241,000/µL, aspirin and clopidogrel were resumed. The patient was discharged without any significant bleeding complications. During 25 months of subsequent outpatient follow-up, platelet counts remained stable without recurrent severe thrombocytopenia. The perioperative course is summarized in Table 1 and Fig. 1.
The diagnosis of DITP relies heavily on clinical reasoning and the exclusion of other causes, as specific diagnostic tests are frequently unavailable [4]. Here, the diagnosis rested on the exclusion of other etiologies, the timing of drug exposure relative to thrombocytopenia, and the rapid platelet recovery after discontinuation, and is therefore best regarded as clinically probable rather than serologically confirmed.
The mechanism of ceftriaxone-associated DITP is thought to involve drug-dependent platelet antibodies (DDPA) that bind specific platelet glycoproteins (GPIIb/IIIa or GPIb/IX) only in the presence of the drug, causing immune-mediated destruction [1,5]. In our case, the Naranjo Adverse Drug Reaction Probability Scale yielded a score of 7 (“probable”) [7]. Because disease-specific criteria are preferred for DITP, we additionally applied the established clinical criteria of George et al. [8] for DITP: ceftriaxone preceded the thrombocytopenia with sustained recovery after withdrawal, other drugs were either continued during recovery or unlikely as causes based on their timing, and other causes were excluded—satisfying a probable classification (rechallenge was not performed for safety) (Table 2).
Competing causes were systematically evaluated and considered unlikely (Table 3). Normal PT/INR, normal LDH and bilirubin, and the absence of schistocytes did not support DIC; the mildly prolonged aPTT and mildly elevated D-dimer were most plausibly attributable to residual heparin from the same-day hemodialysis and the underlying ESRD, although anti-Xa and fibrinogen were not measured. HIT was unlikely (4Ts low probability, no thrombosis), and a platelet nadir below 20,000/µL is uncommon in HIT [9]. Sepsis and thrombotic microangiopathy were also unlikely given the negative culture, normal white blood cell count at the nadir, absence of schistocytes, and rapid recovery. The elevated MPV at the nadir (18.1 fL) with a decrease during early recovery (11.3 fL) was compatible with increased platelet turnover [10], consistent with a peripheral destructive process.
Ceftriaxone is often used in ESRD without dose adjustment because of its dual renal and biliary excretion [11]. However, its clearance is reduced in hemodialysis patients [12], and its half-life is prolonged to approximately 12–17 hours in ESRD, nearly twice that in normal renal function [13]. While typical DITP latency is 5 to 10 days, our case showed a platelet drop within 4 days followed by prompt platelet recovery. Because serum concentrations and DDPA testing were unavailable, impaired clearance cannot be established as the cause; altered drug exposure in ESRD may have contributed to the severity or duration, but this remains speculative.
A review of reported cases illustrates the variable influence of renal function on ceftriaxone-associated DITP (Table 4) [6,14-18]. We searched PubMed (“ceftriaxone” AND “thrombocytopenia”; English; through 2025) for reports with extractable renal status, latency, nadir, and outcome, separating normal from impaired renal function. Conference abstracts, including a 2025 World Congress of Nephrology report indexed in Kidney International Reports, were screened but excluded because they lacked sufficient extractable clinical detail for structured comparison. Reported cases with normal or unspecified renal function generally showed onset around 6 to 10 days with recovery after cessation [14-17], whereas renal impairment was associated with more variable courses—prolonged, occasionally fatal thrombocytopenia [6,18] or, as here, an accelerated 4-day onset. This discrepancy with the prolonged courses reported by Jacquot et al. [18] and Sharma et al. [6] suggests that intercase variability is multifactorial, reflecting dialysis schedule and modality, ceftriaxone dosing and timing, concomitant medications, individual immunologic susceptibility, and prior beta-lactam exposure rather than drug clearance alone.
This patient had received cefazolin, a beta-lactam, before ceftriaxone. Although DDPA are generally drug-specific and cross-sensitization between cephalosporins is not established, prior beta-lactam exposure could in principle have contributed to immune priming and a shortened latency, though this link remains uncertain.
Because the nerve blocks preceded ceftriaxone and the preoperative platelet count was normal, this case is not a direct example of regional anesthesia complicated by unrecognized DITP. It nonetheless illustrates a hypothetical hazard: had severe DITP been present or developed earlier, the bleeding-risk profile of any invasive procedure—including nerve blocks, catheter manipulation, or dialysis anticoagulation—could have changed abruptly. Consistent with individualized regional-anesthesia guidance [19], clinicians should reassess bleeding risk whenever severe thrombocytopenia develops postoperatively.
The principal limitation is the lack of in vitro DDPA testing for definitive confirmation; fibrinogen, haptoglobin, reticulocyte count, anti-Xa activity, and platelet factor 4/heparin antibody testing were also unavailable. Nevertheless, the temporal causality, a Naranjo score of 7, concordant George criteria, the supportive MPV trend, and the exclusion of other etiologies provide reasonable support for the diagnosis. Where DDPA assays are inaccessible, prompt discontinuation of the suspected agent based on clinical reasoning remains the key intervention.
In conclusion, although ceftriaxone offers pharmacokinetic convenience in ESRD, it may rarely be associated with severe, rapid-onset DITP, and the contribution of altered clearance remains uncertain. Anesthesiologists should remain vigilant when unexplained perioperative thrombocytopenia occurs, ensuring immediate drug cessation and reassessing bleeding risk before further invasive procedures.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: HGP, WJ. Data curation: HGP. Formal analysis: HGP. Investigation: HGP, WJ. Methodology: HGP, WJ. Project administration: HGP. Resources: HGP, YHC. Supervision: WJ. Validation: YHC. Visualization: HGP. Writing–original draft: HGP. Writing–review & editing: HGP, WJ, YHC. All authors have read and approved the final manuscript.

Fig. 1.
Platelet count trend and key perioperative events. Ceftriaxone was started on postoperative day (POD) 3 and discontinued on POD 7. On POD 7, the platelet count decreased to 9×10³/µL before hemodialysis and 3×10³/µL after hemodialysis. It subsequently reached <5×10³/µL at the tertiary hospital and recovered to 32×10³/µL by POD 8. Eight units of platelet concentrates were transfused on POD 10. ED, emergency department; CBC, complete blood count; PC, platelet concentrate.
kmj-26-171f1.jpg
Table 1.
Perioperative timeline, dialysis anticoagulation, and key laboratory data
Time point Platelet (×10³/µL) Key event and laboratory data
Preoperative year 130–160 Stable baseline during maintenance hemodialysis.
Postoperative day
 0 151 Heparin-free HD. ORIF under ultrasound-guided femoral and popliteal sciatic nerve blocks; no NSAIDs for analgesia.
 1 Not checked Central venous catheter inserted; cefazolin prophylaxis ongoing.
 2 126 Fever 37.9°C after routine HD (heparin 1,000+500 IU); CRP 14.8 mg/dL; blood culture no growth at 5 days.
 3 Not checked Ceftriaxone 2 g/day started.
 7 (pre-HD, our hospital) 9 Abrupt platelet fall before the heparin-anticoagulated HD; hemodynamically stable, no bleeding.
 7 (post-HD, our hospital) 3 Further decline after heparin-anticoagulated HD (1,000+500 IU); in-house smear: severe platelet decrease, no clumping/schistocytes. Ceftriaxone discontinued; transfer.
 7 (tertiary) <5 MPV 18.1 fL (↑; reference 7.2–11.1). PT 13.7 sec, INR 1.07 (normal); aPTT 50.0 sec (↑); D-dimer 1.48 µg/mL (↑); LDH 196 U/L and bilirubin normal. Fibrinogen not measured.
 8 (tertiary) 32 MPV 11.3 fL. Recovery without transfusion. Hematology favored DITP; quinolone recommended.
 8 (our hospital) 11 Repeat complete blood count; ciprofloxacin started.
 9 38 Heparin-free HD. Hematochezia approximately 230 g; Hb 8.2 g/dL (from 10.8). Conservative management; no transfusion.
 10 66 Hb 7.9 g/dL; 8 units of platelet concentrates transfused.
 11 224 Heparin-free HD. Marked platelet increase.
 14 241 Aspirin and clopidogrel resumed; discharged.
Follow-up (25 mo) 123–174 Stable outpatient counts; no recurrent severe thrombocytopenia.

The patient's outpatient baseline was 130–160×10³/µL (institutional reference range, 150–350×10³/µL).

HD, hemodialysis; ORIF, open reduction and internal fixation; NSAID, nonsteroidal anti-inflammatory drug; CRP, C-reactive protein; MPV, mean platelet volume; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; DITP, drug-induced immune thrombocytopenia; Hb, hemoglobin.

Table 2.
Case-specific application of structured causality assessment tools
Assessment tool Result Case-specific rationale
Naranjo Adverse Drug Reaction Probability Scale 7 (probable) Temporal association with ceftriaxone; recovery after withdrawal; objective confirmation by repeated CBC and smear. The “no alternative causes” item (+2) reflects systematic exclusion: sepsis (negative culture, normal WBC at nadir), HIT (4Ts 2, severe thrombocytopenia before heparin-anticoagulated dialysis), DIC (normal PT/INR, normal LDH/bilirubin), thrombotic microangiopathy (no schistocytes), and concomitant drugs (cefazolin given before the stable POD 2 count; no NSAIDs). Rechallenge and drug-level testing not performed.
George criteria for DITP Probable Ceftriaxone preceded thrombocytopenia with sustained recovery after withdrawal; other drugs were continued or unlikely by timing; other causes were excluded. Rechallenge not performed (unsafe).
4Ts score for HIT 2 (low probability) Extremely low nadir; no thrombosis; severe thrombocytopenia already present before the POD 7 heparin-anticoagulated dialysis; PF4/heparin antibody not tested.

Full instrument questionnaires are not reproduced; sources are cited [7,8]. In the Naranjo scale, the +2 for the alternative-cause item reflects the absence of an alternative cause more likely than ceftriaxone, not absolute exclusion; residual diagnostic uncertainty is acknowledged in the text.

CBC, complete blood count; WBC, white blood cell; HIT, heparin-induced thrombocytopenia; DIC, disseminated intravascular coagulation; PT/INR, prothrombin time/international normalized ratio; LDH, lactate dehydrogenase; POD, postoperative day; NSAID, nonsteroidal anti-inflammatory drug; DITP, drug-induced immune thrombocytopenia; PF4, platelet factor 4.

Table 3.
Differential diagnosis for abrupt postoperative thrombocytopenia
Diagnostic consideration Findings considered Interpretation
Ceftriaxone-associated DITP Abrupt fall 4 days after exposure; nadir <5×10³/µL; rapid recovery without transfusion; elevated MPV; Naranjo 7; George criteria probable. Clinically probable; not serologically confirmed.
Pseudothrombocytopenia Repeat counts at two laboratories; no platelet clumping on smear. Excluded.
Thrombotic microangiopathy No schistocytes; normal LDH and bilirubin. Haptoglobin and reticulocytes unavailable. Unlikely.
Disseminated intravascular coagulation Normal PT/INR; isolated aPTT prolongation and mild D-dimer elevation, presumptive residual heparin; fibrinogen and anti-Xa not measured. Overt DIC not supported; biochemical exclusion incomplete.
Heparin-induced thrombocytopenia Severe thrombocytopenia before POD 7 dialysis; nadir <10×10³/µL; no thrombosis; 4Ts 2; PF4 antibody not tested. Low probability.
Sepsis-associated thrombocytopenia Fever/CRP on POD 2; culture no growth at 5 days; normal WBC at nadir; rapid recovery. Unlikely as primary cause.
Cefazolin or other prior drugs Cefazolin POD 0–2; platelet count 126×10³/µL on POD 2; collapse only after ceftriaxone. Less likely based on the temporal pattern.

DITP, drug-induced immune thrombocytopenia; MPV, mean platelet volume; LDH, lactate dehydrogenase; PT/INR, prothrombin time/international normalized ratio; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; POD, postoperative day; PF4, platelet factor 4; CRP, C-reactive protein; WBC, white blood cell count.

Table 4.
Selected reports of ceftriaxone-associated immune thrombocytopenia by renal status
Study Age/sex Renal status Latency; nadir Course and outcome
Piedra Abusharar et al. [15] (2019) 71/F Normal Approximately 6 day; <1×10³/µL Antibody-confirmed; recovery after discontinuation; survived.
Plas et al. [14] (2025) Adult Normal (miliary tuberculosis) Several days; severe Antibody-confirmed as ceftriaxone (not tuberculostatics); culprit identification preserved first-line anti-TB therapy; survived.
Kumar et al. [17] (2021) Adult Normal (meningoencephalitis) Several days; severe Recovery after switch to ampicillin; survived.
Aryal et al. [16] (2025) Adult Not specified (sepsis) Approximately 1 wk; 18×10³/µL Antibody-confirmed; initially treated as HIT before DITP confirmed; diagnostic confusion.
Sharma et al. [6] (2021) 62/F ESRD on hemodialysis Approximately 12 day; 5×10³/µL Delayed recovery (approximately 9 days); survived.
Jacquot et al. [18] (2013) 65/F Hepatic and renal insufficiency Approximately 7 day; approximately 3×10³/µL Persistent thrombocytopenia; fatal.
Present case 68/F ESRD on maintenance hemodialysis 4 day; 3×10³/µL Early recovery; sustained; survived.

Cases are grouped by renal status (normal vs. impaired).

F, female; TB, tuberculosis; HIT, heparin-induced thrombocytopenia; DITP, drug-induced immune thrombocytopenia; ESRD, end-stage renal disease.

  • 1. Vayne C, Guery EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med 2020;9:2212.ArticlePubMedPMC
  • 2. Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program 2018;2018:576–83.ArticlePubMedPMCPDF
  • 3. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009;7:911–8.ArticlePubMedPMC
  • 4. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013;27:137–45.ArticlePubMedPMC
  • 5. Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 2004;44:1033–40.ArticlePubMedPDF
  • 6. Sharma A, Mannuru D, Matta A, Kaushal A. Rare complication of ceftriaxone therapy: drug-induced thrombocytopenia (DITP). BMJ Case Rep 2021;14:e245228.ArticlePubMedPMC
  • 7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.ArticlePubMed
  • 8. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886–90.ArticlePubMedPDF
  • 9. Greinacher A. Clinical practice: heparin-induced thrombocytopenia. N Engl J Med 2015;373:252–61.ArticlePubMed
  • 10. Kaito K, Otsubo H, Usui N, Yoshida M, Tanno J, Kurihara E, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005;128:698–702.ArticlePubMed
  • 11. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. American College of Physicians; 2007.
  • 12. Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet 2006;45:493–501.ArticlePubMed
  • 13. Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984;25:438–42.ArticlePubMedPMCPDF
  • 14. Plas M, Kampschreur LM, Kroes JA, Porcelijn L, Bethlehem C. Ceftriaxone-induced thrombocytopenia during tuberculosis treatment: a case report. Eur J Hosp Pharm 2025;32:385–7.ArticlePubMed
  • 15. Piedra Abusharar S, Shah N, Patel R, Jain R, Polimera HV. A case of confirmed ceftriaxone-induced immune thrombocytopenia. Cureus 2019;11:e4688.PubMedPMC
  • 16. Aryal B, Simmons A, Ekkurthi G, Panthi B, Pena-Vizcarra OR. Ceftriaxone-induced thrombocytopenia: a case report on a rare medical condition. Cureus 2025;17:e83811.ArticlePubMedPMC
  • 17. Kumar AA, Vijay V, Arya M, Vasant PK, Chandra S, Menon AC. Ceftriaxone-induced thrombocytopenia in a patient with bacterial meningoencephalitis. J Pharmacol Pharmacother 2021;12:175–6.
  • 18. Jacquot C, Moayeri M, Kim B, Shugarts S, Lynch KL, Leavitt AD. Prolonged ceftriaxone-induced immune thrombocytopenia due to impaired drug clearance: a case report. Transfusion 2013;53:2715–21.ArticlePubMed
  • 19. Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fifth edition). Reg Anesth Pain Med 2025;rapm-2024-105766.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy
        Close
      • Download Citation
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Clinically probable ceftriaxone-associated immune thrombocytopenia after foot surgery under peripheral nerve blocks in a hemodialysis patient: a case report
        Close
      • XML DownloadXML Download
      Figure
      • 0
      Clinically probable ceftriaxone-associated immune thrombocytopenia after foot surgery under peripheral nerve blocks in a hemodialysis patient: a case report
      Image
      Fig. 1. Platelet count trend and key perioperative events. Ceftriaxone was started on postoperative day (POD) 3 and discontinued on POD 7. On POD 7, the platelet count decreased to 9×10³/µL before hemodialysis and 3×10³/µL after hemodialysis. It subsequently reached <5×10³/µL at the tertiary hospital and recovered to 32×10³/µL by POD 8. Eight units of platelet concentrates were transfused on POD 10. ED, emergency department; CBC, complete blood count; PC, platelet concentrate.
      Clinically probable ceftriaxone-associated immune thrombocytopenia after foot surgery under peripheral nerve blocks in a hemodialysis patient: a case report
      Time point Platelet (×10³/µL) Key event and laboratory data
      Preoperative year 130–160 Stable baseline during maintenance hemodialysis.
      Postoperative day
       0 151 Heparin-free HD. ORIF under ultrasound-guided femoral and popliteal sciatic nerve blocks; no NSAIDs for analgesia.
       1 Not checked Central venous catheter inserted; cefazolin prophylaxis ongoing.
       2 126 Fever 37.9°C after routine HD (heparin 1,000+500 IU); CRP 14.8 mg/dL; blood culture no growth at 5 days.
       3 Not checked Ceftriaxone 2 g/day started.
       7 (pre-HD, our hospital) 9 Abrupt platelet fall before the heparin-anticoagulated HD; hemodynamically stable, no bleeding.
       7 (post-HD, our hospital) 3 Further decline after heparin-anticoagulated HD (1,000+500 IU); in-house smear: severe platelet decrease, no clumping/schistocytes. Ceftriaxone discontinued; transfer.
       7 (tertiary) <5 MPV 18.1 fL (↑; reference 7.2–11.1). PT 13.7 sec, INR 1.07 (normal); aPTT 50.0 sec (↑); D-dimer 1.48 µg/mL (↑); LDH 196 U/L and bilirubin normal. Fibrinogen not measured.
       8 (tertiary) 32 MPV 11.3 fL. Recovery without transfusion. Hematology favored DITP; quinolone recommended.
       8 (our hospital) 11 Repeat complete blood count; ciprofloxacin started.
       9 38 Heparin-free HD. Hematochezia approximately 230 g; Hb 8.2 g/dL (from 10.8). Conservative management; no transfusion.
       10 66 Hb 7.9 g/dL; 8 units of platelet concentrates transfused.
       11 224 Heparin-free HD. Marked platelet increase.
       14 241 Aspirin and clopidogrel resumed; discharged.
      Follow-up (25 mo) 123–174 Stable outpatient counts; no recurrent severe thrombocytopenia.
      Assessment tool Result Case-specific rationale
      Naranjo Adverse Drug Reaction Probability Scale 7 (probable) Temporal association with ceftriaxone; recovery after withdrawal; objective confirmation by repeated CBC and smear. The “no alternative causes” item (+2) reflects systematic exclusion: sepsis (negative culture, normal WBC at nadir), HIT (4Ts 2, severe thrombocytopenia before heparin-anticoagulated dialysis), DIC (normal PT/INR, normal LDH/bilirubin), thrombotic microangiopathy (no schistocytes), and concomitant drugs (cefazolin given before the stable POD 2 count; no NSAIDs). Rechallenge and drug-level testing not performed.
      George criteria for DITP Probable Ceftriaxone preceded thrombocytopenia with sustained recovery after withdrawal; other drugs were continued or unlikely by timing; other causes were excluded. Rechallenge not performed (unsafe).
      4Ts score for HIT 2 (low probability) Extremely low nadir; no thrombosis; severe thrombocytopenia already present before the POD 7 heparin-anticoagulated dialysis; PF4/heparin antibody not tested.
      Diagnostic consideration Findings considered Interpretation
      Ceftriaxone-associated DITP Abrupt fall 4 days after exposure; nadir <5×10³/µL; rapid recovery without transfusion; elevated MPV; Naranjo 7; George criteria probable. Clinically probable; not serologically confirmed.
      Pseudothrombocytopenia Repeat counts at two laboratories; no platelet clumping on smear. Excluded.
      Thrombotic microangiopathy No schistocytes; normal LDH and bilirubin. Haptoglobin and reticulocytes unavailable. Unlikely.
      Disseminated intravascular coagulation Normal PT/INR; isolated aPTT prolongation and mild D-dimer elevation, presumptive residual heparin; fibrinogen and anti-Xa not measured. Overt DIC not supported; biochemical exclusion incomplete.
      Heparin-induced thrombocytopenia Severe thrombocytopenia before POD 7 dialysis; nadir <10×10³/µL; no thrombosis; 4Ts 2; PF4 antibody not tested. Low probability.
      Sepsis-associated thrombocytopenia Fever/CRP on POD 2; culture no growth at 5 days; normal WBC at nadir; rapid recovery. Unlikely as primary cause.
      Cefazolin or other prior drugs Cefazolin POD 0–2; platelet count 126×10³/µL on POD 2; collapse only after ceftriaxone. Less likely based on the temporal pattern.
      Study Age/sex Renal status Latency; nadir Course and outcome
      Piedra Abusharar et al. [15] (2019) 71/F Normal Approximately 6 day; <1×10³/µL Antibody-confirmed; recovery after discontinuation; survived.
      Plas et al. [14] (2025) Adult Normal (miliary tuberculosis) Several days; severe Antibody-confirmed as ceftriaxone (not tuberculostatics); culprit identification preserved first-line anti-TB therapy; survived.
      Kumar et al. [17] (2021) Adult Normal (meningoencephalitis) Several days; severe Recovery after switch to ampicillin; survived.
      Aryal et al. [16] (2025) Adult Not specified (sepsis) Approximately 1 wk; 18×10³/µL Antibody-confirmed; initially treated as HIT before DITP confirmed; diagnostic confusion.
      Sharma et al. [6] (2021) 62/F ESRD on hemodialysis Approximately 12 day; 5×10³/µL Delayed recovery (approximately 9 days); survived.
      Jacquot et al. [18] (2013) 65/F Hepatic and renal insufficiency Approximately 7 day; approximately 3×10³/µL Persistent thrombocytopenia; fatal.
      Present case 68/F ESRD on maintenance hemodialysis 4 day; 3×10³/µL Early recovery; sustained; survived.
      Table 1. Perioperative timeline, dialysis anticoagulation, and key laboratory data

      The patient's outpatient baseline was 130–160×10³/µL (institutional reference range, 150–350×10³/µL).

      HD, hemodialysis; ORIF, open reduction and internal fixation; NSAID, nonsteroidal anti-inflammatory drug; CRP, C-reactive protein; MPV, mean platelet volume; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; DITP, drug-induced immune thrombocytopenia; Hb, hemoglobin.

      Table 2. Case-specific application of structured causality assessment tools

      Full instrument questionnaires are not reproduced; sources are cited [7,8]. In the Naranjo scale, the +2 for the alternative-cause item reflects the absence of an alternative cause more likely than ceftriaxone, not absolute exclusion; residual diagnostic uncertainty is acknowledged in the text.

      CBC, complete blood count; WBC, white blood cell; HIT, heparin-induced thrombocytopenia; DIC, disseminated intravascular coagulation; PT/INR, prothrombin time/international normalized ratio; LDH, lactate dehydrogenase; POD, postoperative day; NSAID, nonsteroidal anti-inflammatory drug; DITP, drug-induced immune thrombocytopenia; PF4, platelet factor 4.

      Table 3. Differential diagnosis for abrupt postoperative thrombocytopenia

      DITP, drug-induced immune thrombocytopenia; MPV, mean platelet volume; LDH, lactate dehydrogenase; PT/INR, prothrombin time/international normalized ratio; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; POD, postoperative day; PF4, platelet factor 4; CRP, C-reactive protein; WBC, white blood cell count.

      Table 4. Selected reports of ceftriaxone-associated immune thrombocytopenia by renal status

      Cases are grouped by renal status (normal vs. impaired).

      F, female; TB, tuberculosis; HIT, heparin-induced thrombocytopenia; DITP, drug-induced immune thrombocytopenia; ESRD, end-stage renal disease.


      KMJ : Kosin Medical Journal
      TOP